The European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting stands as one of the most prominent international academic events in the field of hematology. The 50th annual meeting, EBMT 2024, will be convened in Glasgow, UK, attracting an anticipated attendance of over 5,500 participants. The meeting served as a platform for in-depth discussions on cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies.

（EBMT On-Site Image）

In recent years, China's clinical research has rapidly advanced, accompanied by a growing influence in the global hematology arena. As both witnesses and participants in the evolution of hematology, the GoBroad Medical Team relentlessly pursues innovations for patients with refractory and recurrent diseases, having presented their findings over a hundred times at prestigious international conferences such as EHA, ASH, EBMT, and ASCO. At EBMT 2024, the team showcased six groundbreaking research achievements, spanning from innovative explorations and practices in hematopoietic stem cell transplantation techniques to the combined application of CAR-T therapy with HSCT. By sharing advanced concepts and exploratory achievements, the team once again contributes Chinese wisdom to the world and shares its innovative results on a global scale!

（GoBroad Team at EBMT）

Special Invited Speaker

Title: Promotion of engraftment in TCRαβ+ cell depleted HSCT for patients with thalassemia major

Presenter: Li Chunfu

Institution: Nanfang-Chunfu Children's Institute of Hematology, GoBroad Medical Institute of Hematology (Guangdong Center)

Poster Presentation

Abstract number 00129: Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning including Donor CAR-T Cells for R/R B-Cell Lymphoma and R/R Multiple Myeloma Failing CAR-T Cell Therapy

Presenter: Yang Fan

Authors:Yang Fan, Liu Rui, Fu Zhonghua, Xu Teng, Shi Hui, Malixia, Su Aiguo, Li Ruiting, Feng Shaomei, Lei Yang, Deng Biping, Wu Tong, Ke Xiaoyan (Corresponding Author), Hu Kai (Corresponding Author)

Institution: Beijing GoBroad Boren Hospital

Abstract number 00726: Different Sources of Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: Relationship between Immune Reconstitution, Graft-versus-Host Disease, and Viral Infections

Presenter: Liao Jianyun

Authors: Liao Jianyun, Bu Chao-ke, He LAN, Liu Huaying, Peng Zhiyong, He Jujian, Zhang Weiwei, Xia Yuqian, He Yuelin, Li Chunfu (Corresponding Author)

Institution: Nanfang-Chunfu Children's Institute of Hematology, GoBroad Medical Institute of Hematology(Guangdong Center)

Abstract Number 01036: Autologous Hematopoietic Stem Cell Transplantation Combined with CAR-T Cell Therapy Significantly Improves Progression-Free Survival in Relapsed Refractory Central Nervous System Lymphoma

Presenter: Liu Rui

Authors: Liu Rui, Yang Fan, Xue Fei, Fu Zhonghua, Guo Yuelu, Feng Shaomei, Zheng Peihao, Malixia, Shi Hui, Deng Biping, Ke Xiaoyan (Corresponding Author), Hu Kai (Corresponding Author)

Institution: Beijing GoBroad Boren Hospital

Abstract number 01089: Maintenance Therapy with Olaparib after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Tp53 Mutated Hematologic Malignancies

Presenter: Li Zhihui

Authosr: Li Zhihui, Xu Teng, Guo Yipei, Wang Xianxuan, Wen Xiaopei, Wang Lei, Wang Jingjing, Song Yanzhi, ZHAO Yongqiang, Wu Tong (Corresponding Author)

Institution: Beijing GoBroad Boren Hospital

Abstract number 001315: Nursing Care of a Patient with Refractory and Recurrent Acute Myeloid Leukemia Who Suffered from Extensive Exfoliative Skin Lesions throughout the Body after Secondary HSCT

Presenter: Wang Xiaoxia

Authors: Wang Xiaoxia, Wang Xianxuan, Li Zhihui, Wu Tong(Corresponding Author)

Institution: Beijing GoBroad Boren Hospital

Striving for Excellence

Advancing with Strength in Research and Innovation

The expert team at GoBroad Healthcare Group consistently advances through scientific research and innovation, sharing the voice of Chinese clinical and scientific achievements with the world. Every challenging breakthrough and every effort for excellence aims to improve treatment effectiveness, bringing hope to patients with hematological diseases.

* In the order of abstract numbers